Current issues relating to drug safety especially with regard to the use of biomarkers: A meeting report and progress update

European Journal of Pharmaceutical Sciences

Volumn 30, Issue 2, 2007, Pages 107-112

  Rolan, Paul ^a   Danhof, Meindert ^b   Stanski, Donald ^c   Peck, Carl ^d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b LEIDEN UNIVERSITY   (Netherlands)

^c Center for Drug Evaluation and Research   (United States)

^d School of Pharmacy   (United States)

Author keywords

Biomarker; PK PD modelling; Safety

Indexed keywords

BIOLOGICAL MARKER; CADMIUM; CLARA CELL PROTEIN; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NAPROXEN; SURFACTANT PROTEIN A; SURFACTANT PROTEIN B; SURFACTANT PROTEIN D; TROGLITAZONE;

CARDIOVASCULAR RISK; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC KIT; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; EARLY DIAGNOSIS; HEART INFARCTION; HUMAN; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; OSTEOARTHRITIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT;

BIOLOGICAL MARKERS; DRUG THERAPY; DRUG TOXICITY; HUMANS; MODELS, BIOLOGICAL;

EID: 33846459685     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2006.11.007     Document Type: Review

References (14)

1. Clayton T.A., Lindon J.C., Cloarec O., Antti H., Charuel C., Hanton G., Provost J.-P., Le Net J.-L., Baker D., Walley R.J., Everett J.R., and Nicolson J.K. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440 (2006) 1073-1077
2. Cross J., Lee H., Westelinck A., Nelson J., Grudzinskas C., and Peck C. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999. Pharmacoepidemiol. Drug Saf. 11 (2002) 439-446
3. Danhof M. Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharm. Res. 22 (2005) 1432-1437
4. DiMasi J.A., Hansen R.W., and Grabowski H.G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22 (2003) 151-185
5. Heerdink E.R., Urquhart J., and Leufkens H.G. Changes in prescribed drug doses after market introduction. Pharmacoepidemiol. Drug Saf. 11 (2002) 447-453
6. Hermans C., and Bernard A. Pneumoproteinaemia: a new perspective in the assessment of lung disorders. Eur. Respir. J. 11 (1998) 801-803
7. Hermans C., and Bernard A. Lung epithelium-specific proteins. Characteristics and potential applications as markers. Am. J. Respir. Crit. Care Med. 159 (1999) 646-678
8. Johnstone J.A., Lineberry C.G., Ascher J.A., Davidson J., Khayrallah M.A., Feighner J.P., and Stark P. A 102-center prospective study of seizure in association with bupropion. J. Clin. Psychiatr. 52 (1991) 450-456
9. Jonsson S., and Karlsson M.O. Estimation of dosing strategies aiming at maximizing utility or responder probability, using oxybutynin as an example drug 25 (2005) 123-132
10. Korn, D., Stanski, D., 2005. Drug Development Science: Obstacles and Opportunities for Collaboration Among Academia, Industry and Government, Report of an Invitational Conference. The Association of American Medical Colleges, Food and Drug Administration, Washington, DC.
11. Lasser K.E., Allen P.D., Woolhandler S.J., Himmelstein D.U., Wolfe S.M., and Bor D.H. Timing of new black box warnings and withdrawals for prescription medications. J. Am. Med. Assoc. 287 (2002) 2215-2220
12. Pai M.P., Norenberg J.P., Telepak R.A., Sidney D.S., and Yang S. Assessment of effective renal plasma flow, enzymuria, and cytokine release in healthy volunteers receiving a single dose of amphortericin B desoxycholate. Antimicrob. Agents Chemother. 49 (2005) 3784-3788
13. Robin M., Dong P., Hermans C., Bernard A., Bersten A.D., and Doyle I.R. Serum levels of CC16, SP-A and SP-B reflect tobacco-smoke exposure in asymptomatic subjects. Eur. Respir. J. 20 (2002) 1152-1161
14. Wong R., Tran V., Morhenn V., Hung S.P., Andersen B., Ito E., Wesley Hatfield G., and Benson N.R. Use of RT-PCR and DNA microarrays to characterize RNA recovered by non-invasive tape harvesting of normal and inflamed skin. J. Invest. Dermatol. 123 (2004) 159-167